Obesity denials in California external review
In the California DMHC record, independent physician reviewers decided 1,868 published external-review cases involving obesityand overturned the plan’s denial in 79.2%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for obesity
| Treatment | Decisions | Overturned |
|---|---|---|
| Wegovy | 633 | 89.4% |
| Zepbound | 591 | 92.4% |
| Ozempic | 72 | 75% |
| Mounjaro | 58 | 58.6% |
| Saxenda | 48 | 87.5% |
| Gastric Bypass | 42 | 42.9% |
| Gastric Bypass Surgery | 39 | 56.4% |
| Duodenal Switch | 29 | 55.2% |
| Lap-band Surgery | 24 | 37.5% |
| Bariatric Surgery | 22 | 27.3% |
| Semaglutide | 17 | 82.4% |
| Gastric Bypass With Duodenal Switch | 14 | 28.6% |
| Bariatric Surgery Consultation | 14 | 50% |
| Laparoscopic Sleeve Gastrectomy | 14 | 85.7% |
| Wegovy Solution Auto-injector | 13 | 100% |
| Roux-en-y Gastric Bypass | 13 | 69.2% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 1,779 | 79.9% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 88 | 64.8% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that the patient has requested authorization and coverage for Zepbound. Obesity is a multi-causal chronic disease recognized across a patient’s lifespan resulting from long-term positive energy balance and the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses. The U.S.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Zepbound auto-injector pen. Obesity is a multi-causal chronic disease recognized across a patient’s lifespan resulting from long-term positive energy balance and the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses. The U.S.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Zepbound. Obesity is a multi-causal chronic disease recognized across a patient’s lifespan resulting from long-term positive energy balance and the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses. The U.S.
The patient has requested authorization and coverage for Zepbound solution auto-injector. Obesity is a multi-causal chronic disease recognized across a patient’s lifespan resulting from long-term positive energy balance and the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses. The U.S.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
Fighting a denial for a GLP-1 drug — Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda? We wrote the full playbook: GLP-1 denial evidence guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving obesity, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY